Phase 2 Migraine Trial, Recruiting NCT07616128 Sponsor: Evommune, Inc. Condition: Migraine
Back to Migraine

Phase 2 Migraine Trial, Recruiting

NCT07616128
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are aged 18 to under 65 years old
  • People who have been diagnosed with migraine, with or without aura, according to standard international diagnostic guidelines
  • People who have tried migraine prevention treatments in the past that did not work for them
  • People who are not currently taking any medication to prevent migraines

Who may not be able to join:

  • People who have difficulty telling their migraines apart from other types of headaches, or who have other primary headache conditions
  • People who are currently taking certain medications (confirm with trial site for the specific medications involved)
  • People who have significant medical, mental health, neurological, heart, or blood test abnormalities (confirm with trial site for specific details)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (650) 319-4553

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Evommune, Inc.
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Mean change from baseline in the number of monthly migraine days (MMD)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov